×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
OncLive Staff
The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jason M. Broderick and Kristie L. Kahl
The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted against approving a new drug application for quizartinib for adult patients with relapsed/refractory FLT3-ITD–positive AML.
Beth Fand Incollingo
Christopher Harington Dwyer, founder of CLL Canada and online chat contributor, leaves a legacy of support and knowledge.
Kristie L. Kahl
The Bruton tyrosine kinase inhibitor showed a statistically-significant and clinically-meaningful improvement in progression-free survival in patients with previously-treated CLL.
Andrea Kabacinski, M.S., RN
An extraordinary group of nurses, led by nurse manager Taylor Andrews, B.S., RN, BMTCN, have made it their mission to become fairy godmothers for the patients they care for in the bone marrow transplant unit and to make their wishes come true.
Lois Adelman
When you are first told that you’re sick, very sick, it’s like a kick in the head. It leaves you stunned and not quite sure which way to turn. If you’re as lucky as I was, you have Sandy Allen-Bard, NP, to turn to.
Lynn Aspey
Most people have heard the term "new normal" for individuals living, surviving and struggling with cancer. What actually does that mean?
Gina Columbus
The FDA has approved a supplemental new drug application for Tibsovo as a single agent for the first-line treatment of adult patients with IDH1-mutant acute myeloid leukemia who are 75 years and older or are ineligible to receive intensive chemotherapy.
Kristie L. Kahl
Only half of patients reported their blood cancer was detected while visiting a doctor after experiencing symptoms versus detection during a routine medical test or exam or while under the care of a doctor for another health condition.
Kristie L. Kahl
Risk for disease progression among patients with chronic lymphocytic leukemia over time differed between those with mutated or unmutated disease, showing that gene somatic hypermutation plays a role throughout the disease course.